Celebrating our 10th anniversary – Unlock our special offer today

Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Israel Procedure to acquire medical cannabis export licence updated ...
  • France Bill introduced to try legalising recreational cannabis based on German model ...
  • North Dakota - United States Over 15,000 signatures needed to get adult-use cannabis legalisation on ballot ...
  • Kentucky - United States Bill signed into law makes changes to medical cannabis regulation ...
  • Oklahoma - United States Bill on industrial hemp harvesting, selling, licences to governor for signature ...
  • Slovenia Cannabis public referendum approved with no date set ...
  • Kentucky - United States Medical cannabis amendment bill heads to governor ...
  • Brazil Senate approves making possession of cannabis a crime ...
  • Lithuania State budget allocates funds to testing THC levels in hemp ...
  • Slovenia Proposal approved for referendum on cannabis legalisation ...
  • Morocco Compulsory logo on cannabis products stipulated by ministry ...
  • United States HHS recommends rescheduling cannabis, now passes to DOJ ...
View all
Regulatory reports

CBD classed as pharmaceutical product: Taiwan regulatory report

Written by || 24th January 2019 || Regulatory reports | Health and science | Marketing and retailing | Policy and Politics | Regulation and legislation | GeographiesAsia Taiwan

In our report looking at the regulations governing CBD in Taiwan, we find that CBD is a classified as a pharmaceutical product and the growing of cannabis plants for any purposes including the extraction, and the addition of CBD to cosmetic products, is prohibited.

Free Sample

Download a free sample page of the report

“CBD classed as pharmaceutical product: Taiwan regulatory report”








    I'm already a subscriber

    Login

    Author default picture

    CannIntelligence

    This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

    Our Key Benefits

    The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

    CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

    • Stay informed of any legal and market change in the sector that impacts your organisation
    • Maximise resources by getting market and legal data analysis daily in one place
    • Make smart decisions by understanding how the regulatory and market landscape evolves
    • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

    Thanks for getting in touch with us

    Please leave your enquiry and we will get back to you within 24 hours


      Sign up to our newsletter

      Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis


        See more


        By signing up you agree to our Privacy Policy.